Shows & Panels
Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- American Readiness: Renewable Power and Efficiency Technologies
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal News Radio's National Cyber Security Awareness Month Special Panel Discussion
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- Government Perspectives on Mobility and the Cloud
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- The New Generation of Database
- Reimagining the Next Generation of Government
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Novartis posts profit gain thanks to new drugs
Wednesday - 4/24/2013, 4:27pm EDT
BASEL, Switzerland (AP) -- Swiss pharmaceutical company Novartis AG reported a 6.7 percent increase in profit for the first quarter Wednesday, boosted by new products and emerging markets.
Novartis says its net profit rose to $2.42 billion from $2.27 billion in the same period last year despite declining sales of its blockbuster heart drug Diovan, which lost U.S. patent protection last year.
The Basel-based company said in a statement the increase -- a turnaround from the 18 percent earnings drop in the first quarter of 2012 -- reflected new product launches such as Gilenya for multiple sclerosis and Afinitor for cancer, strength in emerging markets and EU and U.S. drug approvals to offset patent expirations.
The newly launched drugs added $4.2 billion in revenue, almost a third of sales, making up for its estimated $500 million in losses during the quarter because of patent expirations.
But the quarter was notably marked by the controversy over Novartis' outgoing board chairman, Daniel Vasella, who touched off widespread anger for his whopping 72 million Swiss francs ($77 million) severance package that he later declined because of the Swiss public's outcry.
Also Wednesday, Novartis disclosed that its new chairman, Joerg Reinhardt, would be paid 3.8 million francs, split equally between cash and stock, plus receive 2.6 million euros for lost compensation from his former employer. It also said that Ulrich Lehner would receive about 790,000 francs in cash and stock for serving as chairman ad-interim from Feb. 22 until July 31.
Novartis also unexpectedly announced that its chief finance officer, Jon Symonds, is being replaced by Harry Kirsch, the finance head for the pharmaceuticals division.
On Tuesday, the U.S. government filed a civil health care fraud lawsuit against Novartis in New York, claiming it gave kickbacks to pharmacies to switch transplant patients from competitors' drugs to its own.
The suit, which claims the company's actions caused the public to pay tens of millions of dollars for kickback-tainted drugs, seeks unspecified damages and civil penalties. Novartis, which says it disputes the claims and will defend itself, settled fraud charges based on kickbacks less than three years ago.
Shares in Novartis closed down 0.36 percent at 69 francs Wednesday on the Zurich exchange.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.